Evidence map›Paper›PMID 29983880›Full record

ArticleOncotarget2018

Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer.

Karim Boudadi, Daniel L Suzman, Valsamo Anagnostou, Wei Fu, Brandon Luber, Hao Wang, Noushin Niknafs, James R White, John L Silberstein, Rana Sullivan and 18 more

Registry-linked trialOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02601014 (Biomarker-Driven Phase-2 Study of Combined Immune Checkpoint Blockade for AR-V7-Expressing Metastatic Castration-Resistant Prostate Cancer), which is not on this map. Cited by 98 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed, 3 pooled it
17.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02601014 phase2completednot on this map

Biomarker-Driven Phase-2 Study of Combined Immune Checkpoint Blockade for AR-V7-Expressing Metastatic Castration-Resistant Prostate Cancer (STARVE-PC)

TypeinterventionalSponsorSidney Kimmel Comprehensive Cancer Center at Johns HopkinsRan2016 to 2021Enrolled32ConditionsProstate Cancer, Recurrent Prostate Carcinoma, Stage IV Prostate AdenocarcinomaArmsIpilimumab, Nivolumab, Enzalutamide
3 · Its place in the literature

Who cites it

98 citing papers in PubMed, 3 syntheses or guidelines pooled it, 157 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020
    Trial
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

38 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 6 institutions in 1 country.

Karim BoudadiDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Daniel L SuzmanOffice of Hematology and Oncology Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
Valsamo AnagnostouDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Wei FuDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Brandon LuberDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Hao WangDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Noushin NiknafsDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
James R WhiteDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
John L SilbersteinDepartment of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Rana SullivanDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Donna DowlingDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Rana HarbDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Thomas R NirschlDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Brendan A VeenemanDepartment of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
Scott A TomlinsDepartment of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
Yipeng WangEpic Sciences Inc., San Diego, CA, USA.
Adam JendrisakEpic Sciences Inc., San Diego, CA, USA.
Ryon P GrafEpic Sciences Inc., San Diego, CA, USA.
Ryan DittamoreEpic Sciences Inc., San Diego, CA, USA.
Michael A CarducciDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Mario A EisenbergerDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Michael C HaffnerDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Alan K MeekerDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
James R EshlemanDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jun LuoDepartment of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Victor E VelculescuDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Charles G DrakeDepartment of Hematology/Oncology, Columbia University Medical Center, New York, NY, USA.
Emmanuel S AntonarakisDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Johns Hopkins University · USJohns Hopkins Medicine · USEpic Sciences (United States) · USUniversity of Michigan–Ann Arbor · USColumbia University Irving Medical Center · USUnited States Food and Drug Administration · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
Large-Scale Genetic Analyses of Human CancerR01CA121113 · NCI · JOHNS HOPKINS UNIVERSITY · PI ANAGNOSTOU, VALSAMO, VELCULESCU, VICTOR E. · 2006 to 2022
$4.3M
The aberrant androgen receptor underlies abiraterone/enzalutamide resistanceR01CA185297 · NCI · JOHNS HOPKINS UNIVERSITY · PI ANTONARAKIS, EMMANUEL S., LUO, JUN · 2015 to 2018
$1.5M
NCI NIH HHS P30 CA006973NCI NIH HHS R01 CA121113NCI NIH HHS R01 CA185297
6 · The paper itself

Abstract

AR-V7-expressing metastatic prostate cancer is an aggressive phenotype with poor progression-free survival (PFS) and overall survival (OS). Preliminary evidence suggests that AR-V7-positive tumors may be enriched for DNA-repair defects, perhaps rendering them more sensitive to immune-checkpoint blockade. We enrolled 15 metastatic prostate cancer patients with AR-V7-expressing circulating tumor cells into a prospective phase-2 trial. Patients received nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses, then maintenance nivolumab 3 mg/kg every 2 weeks. Targeted next-generation sequencing was performed to determine DNA-repair deficiency (DRD) status. Outcomes included PSA response rates, objective response rates (ORR), PSA progression-free survival (PSA-PFS), clinical/radiographic PFS and OS. Median age of participants was 65, median PSA was 115 ng/mL, 67% had visceral metastases, and 60% had ≥4 prior systemic therapies. Six of 15 men (40%) had DRD mutations (three in

Indexed as

AR-V7DNA repairipilimumabnivolumabprostate cancer

Identifiers

PMID29983880
PMCPMC6033362
OpenAlexW2809493795

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.